Fate of Acute Heart Failure Patients With Mid-Range Ejection Fraction

Circ J. 2018 Jul 25;82(8):2071-2078. doi: 10.1253/circj.CJ-17-1389. Epub 2018 Apr 20.

Abstract

Background: The outcomes of heart failure (HF) with mid-range ejection fraction (HFmrEF) have been rarely studied, and follow-up data on left ventricular ejection fraction (LVEF) are scarse.

Methods and results: Patients were selected from a prospective multicenter registry of patients hospitalized for acute HF and then classified in the improved group if they exhibited %LVEF change ≥5 with follow-up LVEF ≥50%. Follow-up LVEF reported at least 90 days after discharge was used for classification. Of the 3,085 patients with acute HF, 454 were classified in the HFmrEF, and 276 had follow-up data. Of these 276 patients, 34.1% were classified in the improved group. Multivariate analysis revealed that hypertension, higher heart rate, lower serum sodium level, and maintenance therapy with β-blocker were associated with improved LVEF. The survival rate was significantly higher in the improved group than in the other groups. Young age and maintenance therapy with renin-angiotensin system blockers or aldosterone antagonists were significantly associated with better survival in HFmrEF.

Conclusions: One-third of HFmrEF patients showed improved LVEF; moreover, the survival rate in the improved group was higher than the other groups. Renin-angiotensin system blockers and aldosterone antagonists could improve the survival of HFmrEF patients.

Keywords: Acute heart failure; Heart failure with mid-range ejection fraction; Left ventricular ejection fraction.

Publication types

  • Multicenter Study

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Follow-Up Studies
  • Heart Failure / diagnosis
  • Heart Failure / drug therapy
  • Heart Failure / epidemiology
  • Heart Failure / mortality*
  • Humans
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Prognosis
  • Registries
  • Renin-Angiotensin System / drug effects
  • Risk Factors
  • Stroke Volume / physiology*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Mineralocorticoid Receptor Antagonists